AbbVie to Lower Drug Prices Under Trump Deal, Expands TrumpRx Access, Commits USD 100 Billion

Also Read: AbbVie gets USFDA nod for Epkinly, Rituximab, Lenalidomide combo for Follicular Lymphoma

This three-year agreement provides ​AbbVie with exemption from tariffs and future pricing ‌mandates, the ‍company said, adding that further terms ‍of the deal remain confidential.

The Trump administration ‌has been pressing drugmakers to lower prices, as Americans often pay nearly three times more for prescription medicines than patients in other developed nations.

In December, the administration reached agreements with several other major pharmaceutical companies, including ‍Roche , Merck and Gilead, to cut the prices of their medicines for the ‍government's Medicaid ⁠program and ⁠for cash-paying consumers.

Also Read: AbbVie concludes acquisition of Gilgamesh Pharma Bretisilocin

Most Americans with health insurance pay for drugs with set co-pays or co-insurance based on the list price. They may not be helped by TrumpRx, which will direct customers to drugmakers' websites, where they will sell their products to cash-pay customers.